You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Intravenous immunoglobulin as a potential treatment for long COVID
|
|---|---|
| Published in |
Expert Opinion on Biological Therapy, December 2023
|
| DOI | 10.1080/14712598.2023.2296569 |
| Pubmed ID | |
| Authors |
Matthew W. McCarthy |
| Abstract |
On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health (NIH) opened enrollment for the therapeutic arm of the RECOVER initiative, a prospective, randomized study to evaluate new treatment options for long coronavirus disease 2019 (long COVID). One of the first drugs to be studied in this nationwide initiative is intravenous immunoglobulin (IVIG), which will be a treatment option for subjects enrolled in RECOVER-AUTO, a randomized trial to investigate therapeutic strategies for autonomic dysfunction related to long COVID. IVIG is a mixture of human antibodies (human immunoglobulin) that has been widely used to treat a variety of diseases, including immune thrombocytopenia purpura, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy, and certain infections such as influenza, human immunodeficiency virus, and measles. However, the role of IVIG in the treatment of post-COVID-19 conditions is uncertain. This manuscript examines what is known about IVIG in the treatment of long COVID and explores how this therapeutic agent may be used in the future to address this condition. |
X Demographics
The data shown below were collected from the profiles of 79 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 17 | 22% |
| Germany | 4 | 5% |
| United Kingdom | 3 | 4% |
| Bosnia and Herzegovina | 1 | 1% |
| Norway | 1 | 1% |
| Australia | 1 | 1% |
| Ireland | 1 | 1% |
| Canada | 1 | 1% |
| Spain | 1 | 1% |
| Other | 3 | 4% |
| Unknown | 46 | 58% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 69 | 87% |
| Practitioners (doctors, other healthcare professionals) | 6 | 8% |
| Scientists | 3 | 4% |
| Science communicators (journalists, bloggers, editors) | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 5 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 1 | 20% |
| Student > Bachelor | 1 | 20% |
| Researcher | 1 | 20% |
| Other | 1 | 20% |
| Unknown | 1 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 1 | 20% |
| Business, Management and Accounting | 1 | 20% |
| Unknown | 3 | 60% |
Attention Score in Context
This research output has an Altmetric Attention Score of 49. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2024.
All research outputs
#880,550
of 25,810,956 outputs
Outputs from Expert Opinion on Biological Therapy
#14
of 1,992 outputs
Outputs of similar age
#14,122
of 360,090 outputs
Outputs of similar age from Expert Opinion on Biological Therapy
#1
of 11 outputs
Altmetric has tracked 25,810,956 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,992 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,090 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.